Alkem Laboratories announced a solid financial performance for Q3 FY26, achieving 11% year-over-year (YoY) revenue growth, reaching ₹37,368 Million. The company also detailed a strategic move to acquire a majority stake in Swiss medical device firm Occlutech, specializing in cardiac implants. This acquisition aims to establish a significant global footprint in the MedTech sector, supporting Alkem’s long-term growth pillars alongside its core pharmaceutical business.
Q3 FY26 Financial Highlights at a Glance
Alkem Laboratories reported robust standalone and consolidated results for the third quarter ended December 31, 2025 (Q3 FY26). Total Revenue from Operations grew by 10.7% YoY to reach ₹37,368 Million. EBITDA also showed positive momentum, increasing by 9.0% YoY to ₹8,280 Million, translating to an EBITDA Margin of 22.2%. Net Profit (PAT after Non-Controlling Interest) was ₹6,360 Million, marking a 1.6% YoY growth. The company noted an exceptional charge of ₹528 Million in Q3 FY26 related to newly notified Labour Codes.
Geographic Performance Breakdown
The growth was supported by strong performance across both domestic and international markets:
- Domestic Business: Sales grew by 5.5% YoY to ₹24,959 Million, contributing 67.2% of total sales. Despite the overall Indian Pharmaceutical Market (IPM) growing at 10.9%, Alkem achieved a 9.8% growth, outperforming the market in key acute segments.
- International Business: Revenue surged by an impressive 26.6% YoY to ₹12,157 Million. US sales grew by 18.8% YoY to ₹7,533 Million, while Non-US sales saw an exceptional growth of 41.6% YoY to ₹4,624 Million.
Strategic Acquisition in Medical Devices
A major announcement alongside the results was the execution of a binding term sheet to acquire a majority stake in Occlutech Holding AG, a global medical devices company based in Switzerland specializing in minimally invasive cardiac implants, via its subsidiary Alkem MedTech Pvt Ltd. Managing Director Sandeep Singh emphasized that this move establishes a global footprint in medical devices and is expected to become a meaningful growth pillar alongside the Biotech arm, Enzene Biosciences.
Operational and Regulatory Updates
CEO Dr. Vikas Gupta stated the company remains on track for its full-year guidance, highlighting the planned launch of its GLP-1 semaglutide in March 2026 as a key future driver. Furthermore, R&D spending for the quarter was ₹1,390 Million (3.7% of revenue). On the regulatory front, the company continues to maintain high compliance, with several key facilities showing an ‘EIR Received’ status or ‘No observation’ following recent inspections.
Company Context and Industry Position (FY25 Snapshot)
The presentation provided context on Alkem’s standing as of FY25, identifying it as the fifth-largest pharmaceutical company in the Indian market. Key metrics include:
- Market Leadership: Ranked #3 in Prescriptions and #5 by value in the IPM.
- Scale: Total Revenue was ₹1,29,645 Million, with Domestic Revenue contributing 70.2%.
- Brand Strength: Home to 18 brand families worth over ₹1000 Mn+, including the #2 ‘PAN’ biggest brand family in the IPM.
Source: BSE
